Research programme: anti-inflammatory monoclonal antibodies - Sorrento TherapeuticsAlternative Names: Anti-CGRP antibodies - Sorrento Therapeutics; Anti-PD-L1 antibodies - Sorrento Therapeutics; Anti-RAGE antibodies - Sorrento Therapeutics; STI B010X; STI-B120X; STI-B150X
Latest Information Update: 20 May 2014
At a glance
- Originator Sorrento Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Advanced glycosylation end-product receptor antagonists; Calcitonin gene-related peptide antagonists; PDCD 1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 01 May 2014 Preclinical trials in Inflammation in USA (Parenteral)